Our Mission

Our mission is to disrupt the production of therapeutic peptides by introducing continuous peptide manufacturing using our µLOT® technology platform

The µLOT Technology

µLOT® is a unique platform technology for the continuous manufacturing of peptide therapeutics, representing the most significant advancement in Peptide manufacturing since Solid Phase Peptide Synthesis was first introduced by Nobel laureate Robert Bruce Merrifield in 1963.

µLOT® elevates current accepted manufacturing processes to new highly controllable levels by using a unique multi-variant process.

Benefits

Economical & Ecological

Continuous multi-variant
process reduces development times

Countercurrent effect reduces
chemical consumption and
hazardous waste

Reduced energy, material
and space consumption

Quality & Control

High superior quality yields

Low batch-to-batch variations

Low batch failure risk

Manufacturing development
Design Space enabled

Comprehensive in-line analytics
and data acquisition

Flexible & Scalable

True continuous manufacturing process

Up scalable modular system

Super fast temperature regulation
and no gradients

Continuous fast mixing

The inspiration behind the evolution

After examining and reimagining every aspect of peptide synthesis, we engineered a composite ribbon that incorporated the principles of Houghten’s Tea Bag (1985) to represent the function of ribosomes, and the superior mixing capabilities of Ultrasound, to create a robust future proof platform technology that is not only capable of producing high quality therapeutic peptides, but is scalable for low and high productivity, and does so in an efficient, economical, ecological and accountable way.

The µLOT® technology can be adapted to any form of chemistry or process based on a solid-liquid phase interaction.

The result is more than just peptide production; µLOT® is the future of peptide manufacturing.

02:41

02:17

The µLOT® technology can be adapted to any form of chemistry or process based on a solid-liquid phase interaction.

The result is more than just peptide production; µLOT® is the future of peptide manufacturing.

02:41

02:17

µLOT in-depth

Assembly Line

µLOT® is a chemical assembly line approach to continuous manufacturing of Peptides.

Continuous manufacturing

µLOT® delivers true continuous manufacturing; all production stages are performed continuously and simultaneously as the product passes between each stage of the process.

Counter Current

µLOT® utilises a counter current effect allowing the ribbon and fluids to flow in opposite directions. This promotes the efficient use of reagents and solvents. By connecting multiple modules together, the counter current effect can be further enhanced.

Ultrasound

µLOT® employs ultrasound technology to promote thorough mixing of the fluids and resin beads within each ribbon packet.

Ribbon Tracking

µLOT® offers unprecedented levels of in-line analytics and data acquisition. The combination of ribbon tracking, real time process analytics and control establishes the potential for a closed loop validation environment.

Ribbon

µLOT® uses a continuous solid phase ribbon, incorporating packets containing resin beads, to flow through the various chemical stages. The product can then be efficiently chemically cleaved and collected at the end for downstream processing.

Flexibility

µLOT® is modular and therefore infinitely customisable and scalable, with this modular approach it allows a system to be built up quickly

About Swedish Biomimetics 3000

Philanthropist and recipient of The Honoree Award for Visionary and Pioneering Guidance in the Orphan Drug area, Lars-Uno Larsson, founded Swedish Biomimetics’ in 2004.

Based in Hethel, Norfolk, England and Medicon Village, Lund, Sweden, the business is never far from nature in both locations and ethos.

The aim of biomimetics is to use the models, systems, and elements of nature as inspiration for the purpose of solving complex human problems.

By asking the question, ‘what would nature do?’ Swedish Biomimetics are at the forefront of creating platform technologies that promise to advance therapeutic peptide production.

Peptides are of particular interest in the pharmaceutical industry for targeting disease given their high target specificity, high potency and low toxicity. To date, two major barriers have impeded their adoption: high costs of production and route of administration. Significant improvements in the latter has reignited interest in peptides, however the challenge of high cost of production remains unanswered.

By employing good design and developmental practices, SB3000 platform technologies promise to help reduce the effect on the environment, due to reduced chemical consumption and production of waste, and are able to bring the product to market in a more cost effective fashion. All of which is excellent news for manufacturers, patients, for the environment, and for showing an altogether improved business model.